Midatech (AIM: MTPH.L; NASDAQ: MTP), the R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, announces that further to the announcement made on 20 September 2019, its MTD201 Phase 1 study ("Study 102") for the treatment of acromegaly and neuroendocrine tumours (NET) has commenced.
The first cohort of healthy volunteers, 14 out of 28 subjects, received one dose of Sandostatin 100 microgram/1 ml solution for injection on 5 October 2019, which was followed yesterday by a 30mg injection of MTD201 via either the subcutaneous or intramuscular route (subjects were randomised between the two groups). The remaining 14 subjects will undergo the same procedures later this week to complete the dosing phase of the study.
Following MTD201 dosing, all subjects enter a 63 day observation and sampling period. This data will then be analysed, with top line results expected by the end of 2019 or early in 2020.